Yung Vuong serves as a Senior Principal in Advanced Therapies Quality at Eli Lilly and Company, where he leverages over fifteen years of extensive experience in the biologics manufacturing sector. His expertise spans a wide array of critical areas, including manufacturing, quality assurance, engineering, validation,...
Yung Vuong serves as a Senior Principal in Advanced Therapies Quality at Eli Lilly and Company, where he leverages over fifteen years of extensive experience in the biologics manufacturing sector. His expertise spans a wide array of critical areas, including manufacturing, quality assurance, engineering, validation, and regulatory submissions within a cGMP-regulated environment. Yung's current role as the QA Lead for Computer System Validation and Data Integrity at the Cell and Gene Therapies Manufacturing Facility underscores his commitment to ensuring the highest standards of quality and compliance in advanced therapy products.
In this capacity, Yung is instrumental in overseeing the validation of computer systems, ensuring that all processes meet stringent FDA regulations and industry best practices. His focus on data integrity remediation and risk management is vital, particularly as the field of gene therapy evolves rapidly. Yung's technical acumen is further demonstrated through his leadership in facility startup operations, where he has successfully navigated complex challenges associated with equipment qualification and change control.
Key projects under Yung's guidance include the implementation of robust quality frameworks that enhance supplier quality and streamline aseptic processing protocols. His proactive approach to DI remediation has not only fortified the integrity of data systems but has also fostered a culture of continuous improvement within the organization. Yung Vuong’s unique blend of technical expertise and leadership in advanced therapies quality positions him as a pivotal figure in Eli Lilly’s mission to deliver innovative and life-changing therapies to patients worldwide.
